The simultaneous detection of HER2 and CA15.3 in breast cancer patients has also been made possible by the development of a voltammetric immunosensor providing another non-invasive and sensitive approach to detection (Marques et al., 2018). This evidence concerns the gene ERBB2 and breast carcinoma.